Lewetiracetam i leczenie padaczki w szczególnych sytuacjach klinicznych

Jastrzębski, Karol; Kacperska, Magdalena Justyna

Journal

Aktualności Neurologiczne

2013 | 13 | 4 | 258–266

Article title

Lewetiracetam i leczenie padaczki w szczególnych sytuacjach klinicznych

Authors

Karol Jastrzębski , Magdalena Justyna Kacperska

Content

Full texts:

258-266 Neurologia 4_2013_Jastrzebski_Lewetiracetam.pdf

Download

Title variants

Levetiracetam and therapy of epilepsy in specific clinical situations

Languages of publication

Abstracts

Padaczka (epilepsia) to przewlekłe i częste schorzenie neurologiczne, wymagające długotrwałego stosowania leków przeciwpadaczkowych. Liczne i złożone objawy tego skomplikowanego procesu patofizjologicznego są wynikiem różnych zaburzeń funkcji mózgu. W leczeniu padaczki nie występuje jeden standardowy sposób postępowania. Głównym i podstawowym celem leczenia padaczki jest całkowita kontrola napadów i zminimalizowanie objawów niepożądanych spowodowanych terapią lekami przeciwpadaczkowymi. Ogromne znaczenie ma indywidualne dopasowanie leku do każdego pacjenta. Lek powinien być dostosowany do typu napadu lub zespołu padaczkowego, częstości i ciężkości napadów. Pojawienie się leków nowej generacji dało im pewną przewagę w stosunku do leków starszej generacji. Jednym z dostępnych na rynku leków przeciwpadaczkowych jest lewetiracetam, występujący w postaci podłużnych tabletek. Można go stosować w monoterapii u pacjentów od 16. roku życia z nowo rozpoznaną padaczką, w leczeniu napadów padaczkowych o początku ogniskowym z wtórnym uogólnieniem lub bez wtórnego uogólnienia. Lewetiracetam można również dodawać do terapii innymi lekami przeciwpadaczkowymi, w leczeniu m.in. napadów padaczkowych o początku ogniskowym z wtórnym uogólnieniem lub bez wtórnego uogólnienia u dzieci od 1 miesiąca życia, drgawek mioklonicznych (u pacjentów w wieku powyżej 12 lat z młodzieńczą padaczką miokloniczną) czy pierwotnych uogólnionych napadów toniczno-klonicznych u pacjentów powyżej 12 lat z idiopatyczną padaczką uogólnioną. Lek ten między innymi pomaga w stabilizowaniu aktywności elektrycznej w mózgu i zapobiega napadom.

Epilepsy is a chronic, frequently encountered neurological disease, demanding long-term treatment with antiepileptic drugs (AEDs). It involves high treatment expenses. Epilepsy is a complex pathophysiological process, the numerous and complex symptoms are the result of various disorders of the brain. In the treatment of epilepsy, there is no one standard way to proceed. The main and primary goal of epilepsy treatment is complete seizure control and getting the least side effects during treatment with antiepileptic drugs. It is vital that individual adjustment of the drug for each patient. The drug should be adapted to the type of seizure or seizure team, the frequency and severity of seizures. The emergence of a new generation of drugs gave them a certain advantage over the older generation drugs. Levetiracetam is one of the antiepileptic drugs – the pharmacokinetic profile of levetiracetam has been evaluated in many populations. Overall, levetiracetam has a very favourable pharmacokinetic profile, with rapid absorption following oral administration, excellent bioavailability, quick achievement of steady-state concentrations, linear kinetics, minimal plasma protein binding and without important hepatic metabolism. The mechanism of actions is still unclear. It may be used as monotherapy in patients with newly diagnosed epilepsy, to treat seizures with focal onset with secondary generalization or without secondary generalization. Levetiracetam may also be used supplementary to other antiepileptic drugs in the treatment of seizures of focal onset with secondary generalization or without secondary generalization, myoclonic seizures or primary generalized tonic-clonic seizure. This medicine is very useful tool for clinicians.

Keywords

antiepileptic drugs cytokiny prozapalne epilepsy epileptogenesis epileptogeneza farmakokinetyka inflammation leki przeciwpadaczkowe levetiracetam lewetiracetam padaczka pathogenesis patomechanizm pharmacokinetics pro-inflammatory cytokins terapia padaczki treatment of epilepsy zapalenie

Discipline

MEDICINE: MEDICINE

Publisher

Medical Communications

Journal

Aktualności Neurologiczne

Year

2013

Volume

Issue

Pages

258–266

Physical description

Contributors

author

Karol Jastrzębski

Klinika Neurologii i Epileptologii z Oddziałem Udarowym Uniwersyteckiego Szpitala Klinicznego im. WAM, Uniwersytet Medyczny w Łodzi

author

Magdalena Justyna Kacperska

magda-kacperska@o2.pl

Klinika Neurologii i Epileptologii z Oddziałem Udarowym Uniwersyteckiego Szpitala Klinicznego im. WAM, Uniwersytet Medyczny w Łodzi

References

1. Cendrowski W.: Neuroepidemiologia kliniczna. Volumed, Wrocław 1997.
2. Nadkarni S., LaJoie J., Devinsky O.: Current treatments of epilepsy. Neurology 2005; 64 (12 supl. 3): S2–S11.
3. Ashhab M.U., Omran A., Kong H. i wsp.: Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J. Mol. Neurosci. 2013; 51: 950–958.
4. Voutsinos-Porche B., Koning E., Kaplan H. i wsp.: Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol. Dis. 2004; 17: 385–402.
5. Lehtimäki K.A., Liimatainen S., Peltola J., Arvio M.: The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy. Epilepsy Res. 2011; 95: 184–187.
6. Kim J.E., Choi H.C., Song H.K. i wsp.: Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neurosci. Lett. 2010; 471: 94–99.
7. Rijkers K., Majoie H.J., Hoogland G. i wsp.: The role of interleukin-1 in seizures and epilepsy: a critical review. Exp. Neurol. 2009; 216: 258–271.
8. French J.A., Kanner A.M., Bautista J. i wsp.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261–1273.
9. French J.A., Kanner A.M., Bautista J. i wsp.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252–1260.
10. Kacperska M.J., Jastrzębski K., Kozera-Kępiniak A., Klimek A.: Wybrane farmakokinetyczne interakcje leków w trakcie leczenia padaczki. Część I. Aktualn. Neurol. 2013; 13: 40–49.
11. Jastrzębski K., Kacperska M.J., Kozera-Kępiniak A., Klimek A.: Wybrane farmakokinetyczne interakcje leków w trakcie leczenia padaczki. Część II. Aktualn. Neurol. 2013; 13: 50–55.
12. Perucca E., French J., Bialer M.: Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007; 6: 793–804.
13. Elger C.E., Fernández G.: Options after the first antiepileptic drug has failed. Epilepsia 1999; 40 supl. 6: S9–S12; discussion S73–S74.
14. Berg M.J.: What’s the problem with generic antiepileptic drugs? A call to action. Neurology 2007; 68: 1245–1246.
15. Liow K., Barkley G.L., Pollard J.R. i wsp.; American Academy of Neurology: Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007; 68: 1249–1250.
16. Crawford P., Feely M., Guberman A., Kramer G.: Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006; 15: 165–176.
17. Gower A.J., Noyer M., Verloes R. i wsp.: ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 1992; 222: 193–203.
18. Shorvon S.: Pyrrolidone derivatives. Lancet 2001; 358: 1885–1892.
19. Obeso J.A., Artieda J., Luquin M.R. i wsp.: Antimyoclonic action of piracetam. Clin. Neuropharmacol. 1986; 9: 58–64.
20. Fedi M., Reutens D., Dubeau F. i wsp.: Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch. Neurol. 2001; 58: 781–786.
21. Löscher W., Hönack D.: Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 1993; 232: 147–158.
22. Klitgaard H., Matagne A., Gobert J., Wülfert E.: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998; 353: 191–206.
23. Kasteleijn-Nolst Trenite D.G., i wsp.: Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. 1996; 25: 225–230.
24. Noyer M., Gillard M., Matagne A. i wsp.: The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 1995; 286: 137–146.
25. Sills G.J., Leach J.P., Fraser C.M. i wsp.: Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur. J. Pharmacol. 1997; 325: 35–40.
26. Margineanu D.G., Wülfert E.: Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br. J. Pharmacol. 1997; 122: 1146–1150.
27. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G.: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9–18.
28. Fuks B., Gillard M., Michel P. i wsp.: Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 2003; 478: 11–19.
29. Lynch B.A., Lambeng N., Nocka K. i wsp.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 2004; 101: 9861–9866.
30. Doheny H.C., Ratnaraj N., Whittington M.A. i wsp.: Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999; 34: 161–168.
31. Patsalos P.N.: Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 2000; 85: 77–85.
32. Nicolas J.M., Collart P., Gerin B. i wsp.: In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. 1999; 27: 250–254.
33. Toublanc N., Lacroix B.D., Yamamoto J.: Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities. Drug Metab. Pharmacokinet. 2014; 29: 61–68.
34. Grant R., Shorvon S.D.: Efficacy and tolerability of 1000–4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res. 2000; 42: 89–95.
35. Weinstock A., Ruiz M., Gerard D. i wsp.: Prospective open-label, single-arm, multicenter, safety, tolerability, and pharmacokinetic studies of intravenous levetiracetam in children with epilepsy. J. Child Neurol. 2013; 28: 1423–1429.
36. Reisinger T.L., Newman M., Loring D.W. i wsp.: Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013; 29: 13–18.
37. Dahlin M.G., Wide K., Ohman I.: Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr. Neurol. 2010; 43: 231–235.
38. Italiano D., Perucca E.: Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin. Pharmacokinet. 2013; 52: 627–645.
39. Sharpe C.M., Capparelli E.V., Mower A. i wsp.: A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr. Res. 2012; 72: 43–49.
40. Contin M., Mohamed S., Albani F. i wsp.: Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. Epilepsy Res. 2012; 98: 130–134.
41. Contin M., Albani F., Riva R., Baruzzi A.: Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther. Drug. Monit. 2004; 26: 375–379.
42. Johannessen Landmark C., Baftiu A., Tysse I. i wsp.: Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther. Drug. Monit. 2012; 34: 440–445.
43. Spencer D.D., Jacobi J., Juenke J.M. i wsp.: Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy 2011; 31: 934–941.
44. Meierkord H., Boon P., Engelsen B. i wsp.; European Federation of Neurological Societies: EFNS guideline on the management of status epilepticus in adults. Eur. J. Neurol. 2010; 17: 348–355.
45. Cook A.M., Castle A., Green A. i wsp.: Practice variations in the management of status epilepticus. Neurocrit. Care 2012; 17: 24–30.
46. Misra U.K., Kalita J., Maurya P.K.: Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J. Neurol. 2012; 259: 645–648.
47. Berning S., Boesebeck F., van Baalen A., Kellinghaus C.: Intravenous levetiracetam as treatment for status epilepticus. J. Neurol. 2009; 256: 1634–1642.
48. Lacerda G., Krummel T., Sabourdy C. i wsp.: Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67 (supl. 4): S28–S33.
49. Brockmöller J., Thomsen T., Wittstock M. i wsp.: Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 2005; 77: 529–541.
50. Bilo L., Meo R., de Leva M.F. i wsp.: Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. Clin. Neuropharmacol. 2008; 31: 221–225.
51. Glass G.A., Stankiewicz J., Mithoefer A. i wsp.: Levetiracetam for seizures after liver transplantation. Neurology 2005; 64: 1084–1085.
52. Chabolla D.R., Harnois D.M., Meschia J.F.: Levetiracetam monotherapy for liver transplant patients with seizures. Transplant. Proc. 2003; 35: 1480–1481.
53. Franzoni E., Sarajlija J., Garone C. i wsp.: No kinetic interaction between levetiracetam and cyclosporine: a case report. J. Child Neurol. 2007; 22: 440–442.
54. Brodtkorb E., Mula M.: Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67 (supl. 4): S39–S44.
55. Beavis J., Meek A., Felce D., Kerr M.: A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities. Seizure 2009; 18: 279–284.
56. Hurtado B., Koepp M.J., Sander J.W., Thompson P.J.: The impact of levetiracetam on challenging behavior. Epilepsy Behav. 2006; 8: 588–592.
57. Brodtkorb E., Klees T.M., Nakken K.O. i wsp.: Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav. 2004; 5: 231–235.
58. Aldenkamp A.P., Arzimanoglou A., Reijs R., Van Mil S.: Optimizing therapy of seizures in children and adolescents with ADHD. Neurology 2006; 67 (supl. 4): S49–S51.
59. Bakke K.A., Larsson P.G., Eriksson A.S., Eeg-Olofsson O.: Levetiracetam reduces the frequency of interictal epileptiform discharges during NREM sleep in children with ADHD. Eur. J. Paediatr. Neurol. 2011; 15: 532–538.
60. Gagliano A., Aricò I., Calarese T. i wsp.: Restless Leg Syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. Brain Dev. 2011; 33: 480–486.
61. Larsson P.G., Bakke K.A., Bjørnæs H. i wsp.: The effect of levetiracetam on focal nocturnal epileptiform activity during sleep – a placebo-controlled double-blind cross-over study. Epilepsy Behav. 2012; 24: 44–48.
62. Kellinghaus C., Engbring C., Kovac S. i wsp.: Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure 2008; 17: 27–33.
63. Birbeck G.L., French J.A., Perucca E. i wsp.; Quality Standards Subcommittee of the American Academy of Neurology; Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy: Evidence-based guideline: Antiepileptic drug selection for people with HIV/ AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology 2012; 78: 139–145.
64. Siddiqi O., Birbeck G.L.: Safe treatment of seizures in the setting of HIV/AIDS. Curr. Treat. Options Neurol. 2013; 15: 529–543.
65. Hauser W.A., Annegers J.F., Kurland L.T.: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–468.
66. Burn J., Dennis M., Bamford J. i wsp.: Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 1997; 315: 1582–1587.
67. So E.L., Annegers J.F., Hauser W.A. i wsp.: Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46: 350–355.
68. Arboix A., Comes E., García-Eroles L. i wsp.: Prognostic value of very early seizures for in-hospital mortality in atherothrombotic infarction. Eur. Neurol. 2003; 50: 78–84.
69. Shinton R.A., Gill J.S., Melnick S.C. i wsp.: The frequency, characteristics and prognosis of epileptic seizures at the onset of stroke. J. Neurol. Neurosurg. Psychiatry 1988; 51: 273–276.
70. Kilpatrick C.J., Davis S.M., Tress B.M. i wsp.: Epileptic seizures in acute stroke. Arch. Neurol. 1990; 47: 157–160.
71. Reith J., Jørgensen H.S., Nakayama H. i wsp.: Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke 1997; 28: 1585–1589.
72. Ryvlin P., Montavont A., Nighoghossian N.: Optimizing therapy of seizures in stroke patients. Neurology 2006; 67 (supl. 4): S3–S9.
73. Belcastro V., Pierguidi L., Tambasco N.: Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev. 2011; 33: 289–293.
74. Kilicdag H., Daglıoglu K., Erdogan S. i wsp.: The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum. Dev. 2013; 89: 355–360.
75.Gilad R.: Management of seizures following a stroke: what are the options? Drugs Aging 2012; 29: 533–538.
76. Consoli D., Bosco D., Postorino P. i wsp.; EPIC Study: Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc. Dis. 2012; 34: 282–289.
77. Kutlu G., Gomceli Y.B., Unal Y., Inan L.E.: Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav. 2008; 13: 542–544.
78. Belcastro V., Costa C., Galletti F. i wsp.: Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. Epilepsy Res. 2008; 82: 223–226.
79. Harden C.L., Leppik I.: Optimizing therapy of seizures in women who use oral contraceptives. Neurology 2006; 67 (supl. 4): S56–S58.
80. Coulam C.B., Annegers J.F.: Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20: 519–525.
81. Ragueneau-Majlessi I., Levy R.H., Janik F.: Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002; 43: 697–702.
82. Sabers A., Christensen J.: No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res. 2011; 95: 277–279.

Document Type

article

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.psjd-2c585f1d-49a6-427b-9580-9a8fb55dd013